A previously inactive Bitcoin whale resumed activity on November 6, accumulating 3,009 BTC valued at about $228 million, according to blockchain tracker Lookonchain. This marks a notable return after more than a year of dormancy. Meanwhile, US spot Bitcoin ETFs experienced significant outflows totaling $430.2 million on November 5, reflecting weaker institutional demand. These contrasting movements highlight differing behaviors between large individual holders and institutional investors in the Bitcoin market.
The story of a dormant Bitcoin whale returning contrasts with Pluang's cryptocurrency market snapshot as of Nov 06, 2026 21:21 WIB: out of 50 major cryptocurrencies, only 6 rose while 43 fell. Among notable movers, ATOM dropped 6.51% to Rp25,607 with a typical hold time of 61 days and a 60% buy order activity, ETH fell 6.41% to Rp40,397,122 with a longer hold time of 108 days and predominantly 82% sell orders, and THETA declined 5.82% to Rp2,669 with a 78-day hold time. This shows a generally bearish trend across these assets on Pluang at that time.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
